Purpose: To investigate the long term efficacy of low dose use of cyclosporin-A (Cs-A). Material and Methods: This study was carried out in Kırıkkale University Hospital between 2000-2004. Twentyfour eyes of 12 patients with ocular Behcet's disease using CsA for at least 1 year were included the study. All patients underwent complete ophthalmological and systemic examinations. Renal and liver function tests, complete blood counts, and urine analysis were performed. The period of ocular involvement and mean number of attacks per patient were recorded before and after the treatment. Five mg/kg/days CsA was started in the patients with severe posterior uveitis and this dose was tapered gradually over 2 months to a maintenance dose of 3 mg/kg/days. During the treatment laboratory tests were repeated periodically. When an exacerbation developed, oral prednisone was added to the therapy. Patients were evaluated weekly during the first month and monthly thereafter.Results: All of the patients presented with bilateral panuveitis. Eleven of them were previously treated with corticosteroids and colchicine. The mean CsA administration period was 32.4 months with a range of 18-40 months. The mean number of attacks per patient before and after the treatment were 2.6±0.8 and 0.6±0.5 respectively. The decrease in the mean number of attacks per patient was statistically significant (P<0.001). Visual acuity improved in 5 patients and unchanged in 6 patients, deteriotated in 1 patients. The reason for the decreasein the visual acuity of this patient was cataract in one and optic atrophy in the other eye. No ocular attacks occurred in 3 patients. All the patients tolerated the long term treatment of CsA. Conclusions: The treatment approach with long term and low dose Cs-A play a positive role in the management of ocular Behçet's disease especially preventing recurrences.